Qiagen (1QGEN) Stock Overview
Provides sample to insight solutions that transform biological samples into molecular insights in the Netherlands and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
1QGEN Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Qiagen N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$36.07 |
| 52 Week High | US$47.23 |
| 52 Week Low | US$35.07 |
| Beta | 0.71 |
| 1 Month Change | -16.90% |
| 3 Month Change | -13.15% |
| 1 Year Change | -4.72% |
| 3 Year Change | -25.32% |
| 5 Year Change | -22.15% |
| Change since IPO | -15.71% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1QGEN | IT Life Sciences | IT Market | |
|---|---|---|---|
| 7D | -7.6% | -3.4% | -0.09% |
| 1Y | -4.7% | -12.4% | 13.3% |
Return vs Industry: 1QGEN exceeded the Italian Life Sciences industry which returned -12.4% over the past year.
Return vs Market: 1QGEN underperformed the Italian Market which returned 13.3% over the past year.
Price Volatility
| 1QGEN volatility | |
|---|---|
| 1QGEN Average Weekly Movement | 5.9% |
| Life Sciences Industry Average Movement | 6.6% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in IT Market | 7.7% |
| 10% least volatile stocks in IT Market | 2.8% |
Stable Share Price: 1QGEN's share price has been volatile over the past 3 months compared to the Italian market.
Volatility Over Time: 1QGEN's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of Italian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 5,654 | Thierry Bernard | www.qiagen.com |
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights in the Netherlands and internationally. The company offers primary sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, such as kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, such as assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing.
Qiagen N.V. Fundamentals Summary
| 1QGEN fundamental statistics | |
|---|---|
| Market cap | €7.32b |
| Earnings (TTM) | €371.98m |
| Revenue (TTM) | €1.83b |
Is 1QGEN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1QGEN income statement (TTM) | |
|---|---|
| Revenue | US$2.09b |
| Cost of Revenue | US$702.97m |
| Gross Profit | US$1.39b |
| Other Expenses | US$962.15m |
| Earnings | US$424.88m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.06 |
| Gross Margin | 66.37% |
| Net Profit Margin | 20.33% |
| Debt/Equity Ratio | 43.8% |
How did 1QGEN perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/15 18:22 |
| End of Day Share Price | 2026/03/13 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Qiagen N.V. is covered by 41 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Charles Butler | Barclays |
| Luke Sergott | Barclays |